Profile data is unavailable for this security.
About the company
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
- Revenue in USD (TTM)4.32m
- Net income in USD-5.48m
- Incorporated2011
- Employees16.00
- LocationLipocine Inc675 S Arapeen Dr Ste 202SALT LAKE CITY 84108-1295United StatesUSA
- Phone+1 (801) 994-7383
- Fax+1 (801) 994-7388
- Websitehttps://www.lipocine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CervoMed Inc | 6.16m | -25.58m | 43.67m | 15.00 | -- | 1.68 | -- | 7.09 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| Clene Inc | 214.00k | -30.50m | 45.90m | 75.00 | -- | -- | -- | 214.46 | -3.33 | -3.33 | 0.0231 | -1.21 | 0.0079 | 0.4021 | 0.475 | 2,853.33 | -113.20 | -55.54 | -280.47 | -72.66 | 82.24 | 76.19 | -14,250.47 | -6,165.10 | 1.52 | -8.71 | 3.64 | -- | -47.71 | -- | 20.41 | -- | -- | -- |
| Kezar Life Sciences Inc | 0.00 | -61.71m | 46.14m | 55.00 | -- | 0.556 | -- | -- | -8.44 | -8.44 | 0.00 | 11.33 | 0.00 | -- | -- | 0.00 | -47.14 | -34.75 | -54.13 | -36.82 | -- | -- | -- | -5,003.10 | -- | -- | 0.0742 | -- | -100.00 | -- | 17.80 | -- | -45.57 | -- |
| Cingulate Inc | 0.00 | -22.06m | 46.21m | 13.00 | -- | 10.32 | -- | -- | -5.35 | -5.35 | 0.00 | 0.5811 | 0.00 | -- | -- | 0.00 | -183.12 | -157.80 | -264.65 | -303.36 | -- | -- | -- | -- | -- | -19.54 | 0.4783 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
| Impact Biomedical Inc | 25.00k | -44.19m | 46.62m | 2.00 | -- | -- | -- | 1,864.77 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| UMeWorld Inc | 7.93k | -1.32m | 47.06m | 1.00 | -- | -- | -- | 5,934.66 | -0.0148 | -0.0148 | 0.00009 | -0.0477 | 0.1253 | -- | 1.71 | 7,930.00 | -2,066.65 | -273.32 | -- | -- | -285.62 | -768.98 | -16,497.98 | -13,102.00 | -- | -2.36 | -- | -- | 136.17 | -- | -15.02 | -- | -- | -- |
| Q32 Bio Inc | 0.00 | -42.10m | 47.99m | 26.00 | -- | -- | -- | -- | -3.45 | -3.45 | 0.00 | -1.50 | 0.00 | -- | -- | 0.00 | -51.87 | -36.08 | -61.53 | -39.62 | -- | -- | -- | -870.34 | -- | -- | -- | -- | -100.00 | -- | 57.74 | -- | -67.85 | -- |
| Lipocine Inc | 4.32m | -5.48m | 48.08m | 16.00 | -- | 3.32 | -- | 11.12 | -1.04 | -1.04 | 0.7933 | 2.61 | 0.2351 | -- | 41.82 | 270,168.10 | -29.78 | -30.54 | -32.92 | -34.86 | -- | -- | -126.66 | -194.90 | -- | -- | 0.00 | -- | 492.80 | 132.45 | 100.05 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 48.56m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -28.42m | 48.58m | -- | -- | 6.07 | -- | -- | -1.52 | -1.52 | 0.00 | 0.1911 | 0.00 | -- | -- | -- | -115.28 | -- | -123.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.46 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 50.58m | 2.00 | -- | -- | -- | 208.99 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 50.72m | 21.00 | -- | 7.17 | -- | 9.65 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 51.43m | 75.00 | -- | 0.3999 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 51.82m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 52.89m | 146.00 | -- | 0.3672 | -- | 6.28 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
Data as of Feb 13 2026. Currency figures normalised to Lipocine Inc's reporting currency: US Dollar USD
17.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Squadron Capital Management LLCas of 18 Dec 2025 | 500.00k | 9.01% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 193.80k | 3.49% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 89.27k | 1.61% |
| Geode Capital Management LLCas of 31 Dec 2025 | 62.45k | 1.13% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 37.40k | 0.67% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 26.37k | 0.48% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 24.90k | 0.45% |
| G1 Execution Services LLCas of 30 Sep 2025 | 21.86k | 0.39% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 18.63k | 0.34% |
| Citadel Securities LLCas of 30 Sep 2025 | 14.25k | 0.26% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
